Veliparib With Modified FOLFIRI vs FOLFIRI as Second-Line Treatment of Metastatic Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Clin. Cancer Res 2021 Sep 27;[EPub Ahead of Print], EG Chiorean, KA Guthrie, PA Philip, EM Swisher, F Jalikis, MJ Pishvaian, J Berlin, MS Noel, JM Suga, I Garrido-Laguna, DB Cardin, MR Radke, M Duong, S Bellasea, AM Lowy, HS HochsterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.